TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

Markers in the blood can predict how multiple sclerosis will develop and what drugs will be ­effective, a study found.

Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely to get ...

Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.

Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing ...

Vitamin D is linked to a 34% reduction in the relative risk for disease activity in patients with clinically isolated ...

Researchers have identified biomarkers that can predict disease progression in multiple sclerosis, which could lead to the ...

Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...